U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3921
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    47,504.23
    +799.14 (+1.71%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

U.S. FDA approves GSK unit's long-acting HIV injection

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Jan 21 (Reuters) - The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare.

"This is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month," the FDA said in a statement.

ViiV, in which Pfizer Inc and Shionogi & Co Ltd have small stakes, said that the HIV injection, Cabenuva, will be shipped to wholesalers and specialty distributors in the United States in February.

The monthly injection to suppress the virus that causes AIDS is aimed as an alternative to daily pills.

The Cabenuva injection contains two active ingredients cabotegravir and Janssen's rilpivirine and has previously proven as effective as standard daily pills that have three active ingredients, when given monthly.

The FDA in December 2019 declined to approve the long-acting injection and questioned the treatment's manufacturing process, but not its safety.

ViiV won approval for Cabenuva from Canadian health regulator in March last year.

(Reporting by Aishwarya Nair in Bengaluru; Editing by Vinay Dwivedi)